Duloxetine Hydrochloride
Brand Names: Duloxetine Delayed-Release, Cymbalta
Methodology & AI Transparency ⓘ
Duloxetine Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Duloxetine delayed-release capsules are indicated for the treatment of: ; Major depressive disorder in adults ; Generalized anxiety disorder in adults and pediatric patients 7 years of age and older ; Diabetic peripheral neuropathic pain in adults ; Fibromyalgia in adults ; Chronic musculoskeletal pain in adults Duloxetine delayed-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: ; Major depressive disorder (MDD) in adults ( 1 ) ; Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ).
- 2 Real-world patient consensus: Tracked across 16 patient dosage logs with a 90% satisfaction benchmark (RxCUI 596926).
- 3 Typical cash cost range: Public pharmacy ledger: $5.89 low cash benchmark vs. $34.50 chain retail average ($0.1120/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Duloxetine Hydrochloride: orthostatic hypotension (3.3%), restlessness (3.2%), nausea (9.2%).
Ask our AI Specialists anything about Duloxetine Hydrochloride
Duloxetine Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Duloxetine delayed-release capsules are indicated for the treatment of: ; Major depressive disorder in adults ; Generalized anxiety disorder in adults and pediatric patients 7 years of age and older ; Diabetic peripheral neuropathic pain in adults ; Fibromyalgia in adults ; Chronic musculoskeletal pain in adults Duloxetine delayed-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: ; Major depressive disorder (MDD) in adults ( 1 ) ; Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ).
12.1 Mechanism of Action Although the exact mechanisms of the antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
Following administration (20 mg/1 Capsule, Delayed Release Pellets), Duloxetine Hydrochloride achieves F ≈ 75%–87% systemic availability after standard oral Duloxetine Hydrochloride administration bioavailability and time to peak concentration spans 1 to 2 hrs under duloxetine hydrochloride maintenance onset, governed by a 12 hours terminal elimination (Duloxetine Hydrochloride SPL) terminal half-life through duloxetine hydrochloride undergoes cyp2d6/cyp1a2-mediated hepatic metabolism prior to excretion.
Before initiating Duloxetine Hydrochloride at 20 mg/1 Capsule, Delayed Release Pellets, clinical safety checklists rule out documented intolerance or hypersensitivity reaction involving duloxetine hydrochloride (serotonin and norepinephrine reuptake inhibitor); concurrent restricted medications flagged in section 4/7 of the duloxetine hydrochloride dailymed monograph (596926). Logged tolerability patterns center on nausea (9.2% of reports), headache (8.5% of reports), dizziness (6.9% of reports).
Review concurrent CYP2D6 substrates and inhibitors when titrating Duloxetine Hydrochloride maintenance doses.
Assess baseline hepatic panels and interacting prescriptions when starting Duloxetine Hydrochloride (serotonin and norepinephrine reuptake inhibitor).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Duloxetine Hydrochloride (serotonin and norepinephrine reuptake inhibitor)
- Concurrent restricted medications flagged in Section 4/7 of the Duloxetine Hydrochloride DailyMed monograph (596926)
Logged Side-Effect Incidence (16 Reports)
Duloxetine Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Duloxetine Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy and tolerability of antidepressant drugs in treatment of depression in: What a 6,949-Participant Study Found A total of 33 RCTs were included in 32 articles, involving 6949 patients. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences • 2022-08-01 • Meta-Analysis | N = 6,949 | 99/100 | PMID 37202104 ↗ |
| New Insights on Antidepressants for the treatment of adults with depression in the maintenance: What a 9,384-Participant Study Found Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. Molecular psychiatry • 2023-01-15 • Meta-Analysis | N = 9,384 | 99/100 | PMID 36253442 ↗ |
| New Insights on Efficacy of duloxetine for multisite pain in patients with knee pain due to: What a 353-Participant Study Found These results are consistent with duloxetine enhancing the activity of descending inhibitory pain pathways that are dysfunctional in patients with central sensitization and multisite pain. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association • 2021-01-15 • Phase III Randomized Trial | N = 353 | 93/100 | PMID 32245696 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of duloxetine in patients with knee wear-and-tear joint pain or chronic These results suggest that patients with knee wear-and-tear joint pain who respond well to duloxetine in the first month might experience sustained, long-term pain relief with generally greater quality-of-life improvement than. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association • 2022-05-15 • Phase III Randomized Trial | N = 43 | 88/100 | PMID 33958268 ↗ |
| Can This Approach Help? Inside the Latest Research on Fixed dose combination of low dose pregabalin and duloxetine, or pregabalin Conclusions: A FDC of low doses of pregabalin and duloxetine and high dose of pregabalin single-drug treatment achieved similar pain-relieving with dizziness, and somnolence as the most frequent adverse event. F1000Research • 2023-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38618021 ↗ |
Duloxetine Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1120/unit (~$3.36/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $5.89 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $7.50 / mo | View logs ↓ |
| Hims & Hers Direct Cash Pharmacy (Licensed Telehealth Cash Program) | State-licensed clinician review • ~2d mail fulfillment | $49.00/mo program | Program details |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Duloxetine Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Duloxetine Hydrochloride RxNorm Concept ID | 596926 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1120 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $5.89 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 90.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Duloxetine Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Duloxetine Hydrochloride integrating DailyMed SPL (2025-09-29), CMS NADAC ($0.1120/unit), and 16 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Duloxetine Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.